Latest Entitlement Offers News

Evolution Energy Minerals has announced a $4 million renounceable entitlement offer priced at 1.5 cents per share, including free attaching options, with major shareholder Metals One Plc committing $1 million.

Cosmo Metals Limited has announced a fully underwritten entitlement offer to raise approximately $1.55 million, aimed at advancing drilling and exploration across its key gold and base metals projects. The offer includes new shares and attaching options, with funds earmarked for multiple projects in Western Australia and New South Wales.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

Conico Ltd is set to raise $85,000 through a follow-on share placement at $0.008 per share, targeting strategic shareholders to meet excess demand from its recent entitlement offer.

WAM Active Limited has launched a $51.4 million pro-rata entitlement offer at a 7.8% discount to the recent share price, alongside a $19.3 million institutional placement to meet strong investor demand. The capital raising aims to bolster the company’s proven Australian equity investment strategy while offering shareholders fully franked dividends on new shares.

Cosmo Metals has secured $1.55 million through a fully underwritten entitlement offer to fund near-term drilling at its Kanowna Gold Project in WA and the Bingara and Nundle projects in NSW. The capital raise includes free attaching options, with strong backing from major shareholders and management.

360 Capital Mortgage REIT reported a robust half-year performance with a 40.5% increase in gross assets and a targeted 10.4% distribution yield for FY26, underpinned by disciplined lending and solid capital raising.

360 Capital Mortgage REIT has reported a near doubling of its half-year profit to $2.6 million, driven by a 70% surge in investment income, alongside a successful $16.6 million capital raising. The Trust maintains a strong balance sheet with stable net asset value and a diversified loan portfolio.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.